Tethis S.p.A news

Milan, Italy, September 3, 2024 — Tethis S.p.A., a pioneer in the development of a standardized liquid biopsy platform, announces a collaboration with Weill Cornell Medicine to test  Tethis’ instruments for monitoring the response to curative treatment in patients with early-stage breast cancer. The scientists will collect blood from the patients and will measure the number and kind of tumor cells (cellular residual disease) and DNA (molecular residual disease) releas

Tethis S.p.A, a developer of a novel platform for liquid biopsy testing, announced the appointment of Mr. Bastiaan van der Baan and Mr. Miro Venturi as Independent Members of the Board of Directors.

Bastiaan van der Baan, MSc, is currently Chief Clinical and Business Officer at oncology diagnostics test provider Agendia, where he has helped building up the company’s global clinical and commercial infrastructure. Mr van der Baan holds a degree in molecular sciences and brings ove

Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis’ Liquid Biopsy Platform in Early Stage Breast Cancer and the Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients

Tethis S.p.A announced today that in the first meeting of the reconfirmed Scientific Advisory Board held today, Nicola Aceto PhD, Professor of Molecular Oncology at the Swiss Federal Institute of Technology (ETH) Zurich, has been appointed as its new chairman. Prof. Aceto is a world-renowned leader in circulating tumor cell research, and his work on CTC clusters has been published in the highest ranked scientific journals such as Nature and Cell. Tethis is honored to have prof. Aceto leading